Predicting cholecystocholedochal fistulas in patients with Mirizzi syndrome undergoing endoscopic retrograde cholangiopancreatography

Table 1 Clinical presentation data

	MS with fistula formation, n = 21	MS without fistula formation, n = 96	P value
Age in yr	56 ± 15	57 ± 15	0.72
Sex, male/female	16/5	63/33	0.45
Clinical symptom, n (%)
Abdominal pain	14 (66.67)	86 (77.08)	0.40
Jaundice	15 (71.42)	81 (79.17)	0.56
Cholangitis	10 (47.62)	54 (56.25)	0.48
Laboratory findings
Bilirubin in mg/dL	7.60 ± 7.81	5.87 ± 5.25	0.45
ALK-P in U/L	243.61 ± 162.74	205.20 ± 130.85	0.46
SGOT in U/L	136.53 ± 116.85	197.09 ± 202.04	0.27
SGPT in U/L	226.69 ± 177.39	304.10 ± 290.84	0.47
Leukocytes as × 103/L	11.56 ± 14.02	9.56 ± 3.51	0.55

ALK-P: Alkaline phosphatase; MS: Mirizzi syndrome; SGOT: Serum glutamic-oxaloacetic transaminase; SGPT: Serum glutamic-pyruvic transaminase. Values are means ± SD or number (percentage).

Table 2 Comparison of endoscopic retrograde cholangiopancreatography findings in patients with Mirizzi syndrome with or without cholecystocholedochal fistula formation, n (%)

	MS with fistula formation, n = 21	MS without fistula formation, n = 96	P value
Original findings
Cystic duct opacification	10 (47.61)	46 (47.92)	0.81
GB opacification	16 (76.19)	26 (23.96)	< 0.001
Additional findings
Stricture length > 2 cm	2 (9.52)	41 (42.71)	0.005
CBD stones retrieved	2 (9.52)	28 (29.17)	0.09
Pus in the CBD	10 (47.62)	15 (15.63)	0.003
Duodenal ulcer	6 (28.57)	19 (19.79)	0.39

CBD: Common bile duct; ERCP: Endoscopic retrograde cholangiopancreatography; GB: Gall bladder; MS: Mirizzi syndrome.

Table 3 Predictors of cholecystocholedochal fistulas in patients with Mirizzi syndrome

	Univariate OR	P value	95%CI for OR	Multivariate OR	P value	95%CI for OR
Variate
Stricture length > 2 cm	0.14	0.01	0.03-0.64	0.12	0.008	0.03-0.58
CBD stones retrieved	0.26	0.08	0.06-1.17
Pus in the CBD	4.91	0.002	1.77-13.59	5.82	0.002	1.93-17.58
Duodenal ulcer	1.62	0.38	0.56-4.73

CBD: Common bile duct; CI: Confidence interval; OR: Odds ratio.